GH Research PLC
GHRS15.165USD
+1.505+11.02%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
940.68MValor de mercado
PerdaP/L TTM
Mais detalhes de GH Research PLC Empresa
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Informações de GH Research PLC
Código da empresaGHRS
Nome da EmpresaGH Research PLC
Data de listagemJun 25, 2021
CEOValcheva (Velichka)
Número de funcionários50
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
EndereçoJoshua Dawson House
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 RY95
Telefone35314378334
Site
Código da empresaGHRS
Data de listagemJun 25, 2021
CEOValcheva (Velichka)
Executivos da empresa GH Research PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
Lynx1 Capital Advisors LLC
13.87%
RA Capital Management, LP
12.38%
RTW Investments L.P.
8.98%
Outro
26.65%
Investidores
Investidores
Proporção
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
Lynx1 Capital Advisors LLC
13.87%
RA Capital Management, LP
12.38%
RTW Investments L.P.
8.98%
Outro
26.65%
Tipos de investidores
Investidores
Proporção
Individual Investor
26.78%
Investment Advisor
24.73%
Hedge Fund
22.53%
Venture Capital
13.30%
Investment Advisor/Hedge Fund
10.09%
Research Firm
1.24%
Bank and Trust
0.04%
Outro
1.29%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
98
44.60M
71.90%
-2.17M
2025Q3
79
43.69M
70.44%
-1.29M
2025Q2
81
63.73M
102.74%
+7.16M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
--
--
Sep 30, 2025
Lynx1 Capital Advisors LLC
8.60M
13.87%
+1.85M
+27.48%
Sep 30, 2025
RA Capital Management, LP
7.68M
12.38%
--
--
Sep 30, 2025
RTW Investments L.P.
5.57M
8.98%
+29.11K
+0.53%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.33M
8.59%
+234.90K
+4.61%
Sep 30, 2025
Cormorant Asset Management, LP
1.92M
3.09%
-93.04K
-4.63%
Sep 30, 2025
Terwey (Theis)
1.78M
2.88%
-2.91M
-61.98%
Sep 30, 2025
Deep Track Capital LP
1.25M
2.02%
-750.00K
-37.50%
Sep 30, 2025
Millennium Management LLC
863.60K
1.39%
+659.96K
+324.07%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
AdvisorShares Psychedelics ETF
5.66%
iShares MSCI Ireland ETF
0.87%
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
Proporção5.66%
iShares MSCI Ireland ETF
Proporção0.87%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.76%
SPDR S&P International Small Cap ETF
Proporção0.02%
ALPS Medical Breakthroughs ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
